| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
|
N Engl J Med
|
2015
|
5.07
|
|
2
|
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
|
Lancet Oncol
|
2013
|
4.55
|
|
3
|
A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors.
|
J Thorac Oncol
|
2006
|
1.81
|
|
4
|
Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma.
|
Cancer Sci
|
2013
|
1.22
|
|
5
|
Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
|
Cancer Sci
|
2008
|
1.20
|
|
6
|
A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer.
|
Am J Clin Oncol
|
2007
|
1.07
|
|
7
|
Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.05
|
|
8
|
Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients.
|
Gastric Cancer
|
2012
|
1.04
|
|
9
|
Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases.
|
Cancer Chemother Pharmacol
|
2011
|
1.03
|
|
10
|
Pulmonary tumor thrombotic microangiopathy associated with esophageal squamous cell carcinoma.
|
Intern Med
|
2011
|
1.02
|
|
11
|
Carcinoma coexisting with esophageal leiomyoma.
|
Gastrointest Endosc
|
2002
|
0.96
|
|
12
|
Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial.
|
Jpn J Clin Oncol
|
2013
|
0.94
|
|
13
|
Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
|
Jpn J Clin Oncol
|
2011
|
0.91
|
|
14
|
Altered carbohydrate metabolism in the storage roots of sweet potato plants overexpressing the SRF1 gene, which encodes a Dof zinc finger transcription factor.
|
Planta
|
2009
|
0.91
|
|
15
|
Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice.
|
Cancer Sci
|
2008
|
0.90
|
|
16
|
Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: a retrospective analysis of 12 cases.
|
Cancer
|
2008
|
0.89
|
|
17
|
A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy.
|
Cancer Chemother Pharmacol
|
2010
|
0.88
|
|
18
|
Non-surgical approach to small cell carcinoma of the esophagus: does this rare disease have the same tumor behavior as SCLC?
|
Int J Clin Oncol
|
2011
|
0.88
|
|
19
|
Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck.
|
Jpn J Clin Oncol
|
2013
|
0.87
|
|
20
|
Feasibility study of single agent Cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of the head and neck: preliminary results.
|
Jpn J Clin Oncol
|
2007
|
0.86
|
|
21
|
Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.
|
Jpn J Clin Oncol
|
2006
|
0.86
|
|
22
|
Efficient screening of long terminal repeat retrotransposons that show high insertion polymorphism via high-throughput sequencing of the primer binding site.
|
Genome
|
2014
|
0.84
|
|
23
|
Multicenter phase II study of an opioid-based pain control program for head and neck cancer patients receiving chemoradiotherapy.
|
Radiother Oncol
|
2011
|
0.84
|
|
24
|
A LINE-type retrotransposon active in meristem stem cells causes heritable transpositions in the sweet potato genome.
|
Plant Mol Biol
|
2006
|
0.83
|
|
25
|
Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients.
|
Cancer Sci
|
2006
|
0.83
|
|
26
|
Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
|
Jpn J Clin Oncol
|
2009
|
0.83
|
|
27
|
The effectiveness of chemoradiation therapy and salvage surgery for hypopharyngeal squamous cell carcinoma.
|
Jpn J Clin Oncol
|
2013
|
0.83
|
|
28
|
Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer.
|
Int J Clin Oncol
|
2008
|
0.82
|
|
29
|
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
|
BMC Cancer
|
2014
|
0.82
|
|
30
|
Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors.
|
Int J Clin Oncol
|
2009
|
0.81
|
|
31
|
A Dermatitis Control Program (DeCoP) for head and neck cancer patients receiving radiotherapy: a prospective phase II study.
|
Int J Clin Oncol
|
2012
|
0.81
|
|
32
|
Phase II trial of concurrent chemoradiotherapy with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck: Japan Clinical Oncology Group Study (JCOG0706).
|
Jpn J Clin Oncol
|
2009
|
0.81
|
|
33
|
Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
|
Jpn J Clin Oncol
|
2007
|
0.81
|
|
34
|
Extragonadal germ cell tumors in Japan.
|
Cancer Sci
|
2003
|
0.80
|
|
35
|
Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
|
Jpn J Clin Oncol
|
2010
|
0.80
|
|
36
|
Induction chemotherapy with docetaxel, cisplatin and S-1 followed by proton beam therapy concurrent with cisplatin in patients with T4b nasal and sinonasal malignancies.
|
Jpn J Clin Oncol
|
2012
|
0.79
|
|
37
|
Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
|
Jpn J Clin Oncol
|
2012
|
0.79
|
|
38
|
Clinical significance of KRAS gene mutation and epidermal growth factor receptor expression in Japanese patients with squamous cell carcinoma of the larynx, oropharynx and hypopharynx.
|
Int J Clin Oncol
|
2012
|
0.79
|
|
39
|
Impact of early radiological response evaluation on radiotherapeutic outcomes in the patients with nasal cavity and paranasal sinus malignancies.
|
J Radiat Res
|
2012
|
0.78
|
|
40
|
Accelerated radiotherapy and larynx preservation in favorable-risk patients with T2 or worse hypopharyngeal cancer.
|
Jpn J Clin Oncol
|
2007
|
0.78
|
|
41
|
Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2012
|
0.76
|
|
42
|
Late toxicity of proton beam therapy for patients with the nasal cavity, para-nasal sinuses, or involving the skull base malignancy: importance of long-term follow-up.
|
Int J Clin Oncol
|
2014
|
0.76
|
|
43
|
In vitro antitumor activity of bropirimine against urinary bladder tumor cells.
|
Anticancer Res
|
2002
|
0.76
|
|
44
|
Lenvatinib in radioiodine-refractory thyroid cancer.
|
N Engl J Med
|
2015
|
0.75
|
|
45
|
Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer.
|
Jpn J Clin Oncol
|
2010
|
0.75
|
|
46
|
Influence of delayed tumor clearance on reliability of complete response rate in chemoradiotherapy for head and neck cancer.
|
Jpn J Clin Oncol
|
2007
|
0.75
|
|
47
|
[Pharmacology profile of crizotinib (Xalkori(®)Capsules) and clinical findings on this drug].
|
Nihon Yakurigaku Zasshi
|
2013
|
0.75
|
|
48
|
[Pharmacology profile of sunitinib malate (Sutent) Capsules) and clinical findings on this drug].
|
Nihon Yakurigaku Zasshi
|
2009
|
0.75
|
|
49
|
[5-FU+CDDP(FP) +cetuximab in recurrence/metastasis head and neck cancer].
|
Nihon Rinsho
|
2015
|
0.75
|
|
50
|
[Application of aptamers to medicine: pharmacological profile and results of clinical trials on pegaptanib sodium (Macugen) for age-related macular degeneration].
|
Nihon Yakurigaku Zasshi
|
2009
|
0.75
|
|
51
|
[Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy].
|
Gan To Kagaku Ryoho
|
2009
|
0.75
|
|
52
|
[Retrospective analysis of antiemetic effect in patients receiving cisplatin].
|
Gan To Kagaku Ryoho
|
2011
|
0.75
|
|
53
|
Locoregional control after intensity-modulated radiotherapy for nasopharyngeal carcinoma with an anatomy-based target definition.
|
Jpn J Clin Oncol
|
2013
|
0.75
|
|
54
|
Prospective trial of chemotherapy-enhanced accelerated radiotherapy for larynx preservation in patients with intermediate-volume hypopharyngeal cancer.
|
Head Neck
|
2011
|
0.75
|
|
55
|
[The palliative care in the clinical oncology].
|
Nihon Rinsho
|
2007
|
0.75
|
|
56
|
[Evaluation of clinical response of head and neck cancer patients during induction chemotherapy and chemoradiotherapy].
|
Gan To Kagaku Ryoho
|
2012
|
0.75
|
|
57
|
A pilot study of post-operative radiotherapy with concurrent chemotherapy for high-risk squamous cell carcinoma of the cervical esophagus.
|
Jpn J Clin Oncol
|
2011
|
0.75
|
|
58
|
[Evaluation of aprepitant as a prophylactic antiemetic in the Cisplatin split regimen combined with radiation for patients with head and neck cancer].
|
Gan To Kagaku Ryoho
|
2014
|
0.75
|
|
59
|
Pharmacology profile and clinical findings of bosutinib hydrate (Bosulif(®) Tablets).
|
Nihon Yakurigaku Zasshi
|
2016
|
0.75
|
|
60
|
[Induction chemotherapy followed by chemoradiotherapy for the patients with far-advanced nasopharyngeal carcinoma - our treatment strategy].
|
Gan To Kagaku Ryoho
|
2012
|
0.75
|